You are here: Industry Insights > Oxford Biomedica

News List

Oxford Biomedica joins consortium for promising COVID-19 vaccine pharmatimes
April 08, 2020
As of this morning – Wednesday April 8 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 55,242 with 6,159 deaths
Oxford Biomedica to license LentiVector to Juno pharmatimes
March 19, 2020
Oxford Biomedica has signed a Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s Juno Theraputics, granting the latter a non-exclusive license to the LentiVector platform.
Oxford Biomedica announces R&D collaboration with Microsoft to improve gene and cell therapy manufacturing using the intelligent cloud and machine learning firstwordpharma
March 13, 2019
Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that it has entered into a research and development collaboration with Microsoft Research to improve the yield and quality of next generation gene therapy vectors using
Microsoft unveils new platform to boost therapeutics production pharmaceutical-technology
March 13, 2019
Technology giant Microsoft has unveiled a new platform that will leverage cloud and machine learning to improve gene and cell therapy manufacturing.
Oxford BioMedica unveils digital initiative to streamline manufacturing pharmatimes
November 26, 2018
UK gene and cell therapy group Oxford BioMedica has announced a new digital framework initiative to streamline the production of next-generation medicines.
Axovant buys rights for Oxford BioMedica’s Parkinson’s candidate pharmatimes
June 13, 2018
Biopharmaceutical firm Axovant Sciences has agreed exclusive worldwide rights for the development and commercialisation of gene therapy company Oxford BioMedica’s investigational candidate OXB-102, now known as AXO-Lenti-PD, for the treatment of Parkinson
£2m UK consortium to tackle gene therapy pharmatimes
August 14, 2017
A new consortium, led by Oxford BioMedica, will embark on a two-year, £2 million project focused on gene and cell therapy manufacturing.

Previous page 1 2 Next page